NASDAQ Healthcare Biotechnology ZYME

Zymeworks Inc.

$ 23.14 0.00 %

Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.

CEO: Kenneth H. Galbraith - https://www.zymeworks.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

$40.67 75.76 %

Recommandation

Buy

DCF

$ -18.24

Loading data...

ZYME vs S&P500

Loading data...

No data available.

Quick ratio

10.82

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-16.89

may indicate that the company is undervalued or has poor growth prospects.

EPS

-1.37

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-37.79 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-25.26 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

9.54

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.10

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-1.03

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
4 indicates moderate financial health
Altman score
0.43 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
6.85 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.04 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.